Canaccord analyst Sumant Kulkarni said he likes Atail Life Sciences strategic investment in Beckley and views the presence of catalysts, along with a more streamlined pipeline as something that can make the company easier to understand, and for investors to more easily conceptualize the significant value of the stock relative to the unmet need and sizes of the indications that Atai is targeting. Canaccord reiterated its Buy rating and $11 price target on Atai Life Sciences shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATAI:
- Rising High: Exclusive talk with financial services firm Safe Harbor Financial
- Atai Life Sciences sees cash runway into 2026
- Atai Life Sciences reports Q4 EPS (12c), consensus (16c)
- atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights
- Atai Life announces initial results from Psytech’s Phase 2a study of BPL-003
